24 research outputs found
How to assess success of treatment when using multiple doses: the case of misoprostol for medical abortion.
Background: The assessment of treatment success in clinical trials when multiple (repeated) doses (courses) are involved is quite common, for example, in the case of infertility treatment with assisted reproductive technology (ART), and medical abortion using misoprostol alone or in combination with mifepristone. Under these or similar circumstances, most researchers assess success using binomial proportions after a certain number of consecutive doses, and some have used survival analysis. In this paper we discuss the main problems in using binomial proportions to summarize (the overall) efficacy after two or more consecutive doses of the relevant treatment, particularly for the case of misoprostol in medical abortion studies. We later discuss why the survival analysis is best suited under these circumstances, and illustrate this by using simulated data.
Methods: The formulas required for the binomial proportion and survival analysis (without and with competing risks) approaches are summarized and analytically compared. Additionally, numerical results are computed and compared between the two approaches, for several theoretical scenarios.
Results: The main conceptual limitations of the binomial proportion approach are identified and discussed, caused mainly by the presence of censoring and competing risks, and it is demonstrated how survival analysis can solve these problems. In general, the binomial proportion approach tends to underestimate the ârealâ success rate, and tends to overestimate the corresponding standard error.
Conclusions: Depending on the rates of censored observations or competing events between repeated doses of the treatment, the bias of the binomial proportion approach as compared to the survival analysis approaches varies; however, the use of the binomial approach is unjustified as the survival analysis options are well known and available in multiple statistical packages. Our conclusions also apply to other situations where success is estimated after multiple (repeated) doses (courses) of the treatment
Age at natural menopause among patients with systemic lupus erythematosus
Objective. The aim of this study was to estimate the age at natural menopause in women with SLE. Methods. One thousand and thirty-nine consecutive SLE patients <60 years of age were surveyed. Demographic and clinical data were queried by a single investigator. SLE characteristics and co-morbidities were retrieved from their medical records. Natural menopause was defined as amenorrhoea â„12 months in the absence of previous hysterectomy, CYC exposure and severe chronic kidney disease (SCKD). Pregnant women and those with menses during the 12 months prior to interview were considered premenopausal. Median age at menopause was estimated by both logit and survival analyses. In addition, mean age at menopause was calculated for patients aged â„40 years. Factors associated with age at natural menopause were assessed by Cox regression analysis. Results. A total of 961 SLE women were analysed. At interview, most patients (81.6%) were premenopausal, 7.9% had natural menopause, 6.3% were postmenopausal previously exposed to CYC, 4.1% had undergone hysterectomy before menopause and 0.1% presented with SCKD and amenorrhoea. The mean age at interview was 35.2 years (s.d. 10.1), the mean age at SLE diagnosis was 26.9 years (s.d. 8.6) and the mean duration of disease was 8.2 years (s.d. 7.1). The mean recalled age at menopause was 46.4 years (s.d. 4.7). Median age at menopause estimated by logit and survival analyses were 50.7 and 50.8 years, respectively. Only the age at SLE diagnosis was associated with age at natural menopause. Conclusion. Median age at natural menopause in women with lupus is 50 years. This is consistent with the age at menopause reported in the general populatio
Episiotomy and obstetric outcomes among women living with type 3 female genital mutilation: a secondary analysis
Health systems analysis and evaluation of the barriers to availability, utilisation and readiness of sexual and reproductive health services in COVID-19-affected areas: a WHO mixed-methods study protocol.
Introduction
COVID-19 has led to an unprecedented increase in demand on health systems to care for people infected, necessitating the allocation of significant resources, especially medical resources, towards the response. This, compounded by the restrictions on movement instituted may have led to disruptions in the provision of essential services, including sexual and reproductive health (SRH) services. This study aims to assess the availability of contraception, comprehensive abortion care, sexually transmitted infection prevention and treatment and sexual and gender-based violence care and support services in local health facilities during COVID-19 pandemic. This is a standardised generic protocol designed for use across different global settings.
Methods and analysis
This study adopts both quantitative and qualitative methods to assess health facilitiesâ SRH service availability and readiness, and clientsâ and providersâ perceptions of the availability and readiness of these services in COVID-19-affected areas. The study has two levels: (1) perceptions of clients (and the partners) and healthcare providers, using qualitative methods, and (2) assessment of infrastructure availability and readiness to provide SRH services through reviews, facility service statistics for clients and a qualitative survey for healthcare provider perspectives. The health system assessment will use a cross-sectional panel survey design with two data collection points to capture changes in SRH services availability as a result of the COVID-19 epidemic. Data will be collected using focus group discussions, in-depth interviews and a health facility assessment survey.
Ethics and dissemination
Ethical approval for this study was obtained from the WHO Scientific and Ethics Review Committee (protocol ID CERC.0103). Each study site is required to obtain the necessary ethical and regulatory approvals that are required in each specific country
Prepregnancy and early pregnancy calcium supplementation among women at high risk of pre-eclampsia : a multicentre, double-blind, randomised, placebo-controlled trial
CITATION: Hofmeyr, G. J., et al. 2019. Prepregnancy and early pregnancy calcium supplementation among women at high risk of pre-eclampsia : a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet, 393(10169):P330-339, doi:10.1016/S0140-6736(18)31818-X.The original publication is available at https://www.thelancet.comBackground: Reducing deaths from hypertensive disorders of pregnancy is a global priority. Low dietary calcium
might account for the high prevalence of pre-eclampsia and eclampsia in low-income countries. Calcium
supplementation in the second half of pregnancy is known to reduce the serious consequences of pre-eclampsia;
however, the effect of calcium supplementation during placentation is not known. We aimed to test the hypothesis
that calcium supplementation before and in early pregnancy (up to 20 weeksâ gestation) prevents the development
of pre-eclampsia
Methods: We did a multicountry, parallel arm, double-blind, randomised, placebo-controlled trial in South Africa,
Zimbabwe, and Argentina. Participants with previous pre-eclampsia and eclampsia received 500 mg calcium or
placebo daily from enrolment prepregnancy until 20 weeksâ gestation. Participants were parous women whose most
recent pregnancy had been complicated by pre-eclampsia or eclampsia and who were intending to become pregnant.
All participants received unblinded calcium 1·5 g daily after 20 weeksâ gestation. The allocation sequence (1:1 ratio)
used computer-generated random numbers in balanced blocks of variable size. The primary outcome was
pre-eclampsia, defined as gestational hypertension and proteinuria. The trial is registered with the Pan-African
Clinical Trials Registry, number PACTR201105000267371. The trial closed on Oct 31, 2017.
Findings: Between July 12, 2011, and Sept 8, 2016, we randomly allocated 1355 women to receive calcium or placebo;
331 of 678 participants in the calcium group versus 320 of 677 in the placebo group became pregnant, and 298 of
678 versus 283 of 677 had pregnancies beyond 20 weeksâ gestation. Pre-eclampsia occurred in 69 (23%) of
296 participants in the calcium group versus 82 (29%) of 283 participants in the placebo group with pregnancies
beyond 20 weeksâ gestation (risk ratio [RR] 0·80, 95% CI 0·61â1·06; p=0·121). For participants with compliance
of more than 80% from the last visit before pregnancy to 20 weeksâ gestation, the pre-eclampsia risk was 30 (21%)
of 144 versus 47 (32%) of 149 (RR 0·66, CI 0·44â0·98; p=0·037). There were no serious adverse effects of
calcium reported.
Interpretation: Calcium supplementation that commenced before pregnancy until 20 weeksâ gestation, compared with
placebo, did not show a significant reduction in recurrent pre-eclampsia. As the trial was powered to detect a large
effect size, we cannot rule out a small to moderate effect of this intervention.
ernal and Child Health.https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31818-X/fulltextPublisher's versio
Are women with history of pre-eclampsia starting a new pregnancy in good nutritional status in South Africa and Zimbabwe?
Background
Maternal nutritional status before and during pregnancy is an important contributor to pregnancy outcomes and early child health. The aim of this study was to describe the preconceptional nutritional status and dietary intake during pregnancy in high-risk women from South Africa and Zimbabwe.
Methods
This is a prospective observational study, nested to the CAP trial. Anthropometric measurements before and during pregnancy and dietary intake using 24-h recall during pregnancy were assessed. The Intake Distribution Estimation software (PC-SIDE) was used to evaluate nutrient intake adequacy taking the Estimated Average Requirement (EAR) as a cut-off point.
Results
Three hundred twelve women who had pre-eclampsia in their last pregnancy and delivered in hospitals from South Africa and Zimbabwe were assessed. 73.7 and 60.2% women in South Africa and Zimbabwe, respectively started their pregnancy with BMI above normal (BMIââ„â25) whereas the prevalence of underweight was virtually non-existent. The majority of women had inadequate intakes of micronutrients. Considering food and beverage intake only, none of the micronutrients measured achieved the estimated average requirement. Around 60% of pregnant women reported taking folic acid or iron supplements in South Africa, but almost none did so in Zimbabwe.
Conclusion
We found a high prevalence of overweight and obesity and high micronutrient intake inadequacy in pregnant women who had the previous pregnancy complicated with pre-eclampsia. The obesity figures and micronutrient inadequacy are issues of concern that need to be addressed. Pregnant women have regular contacts with the health system; these opportunities could be used to improve diet and nutrition.
Trial registration
PACTR201105000267371
. Registered 06 December 2010
Posibles funciones de un estadĂstico en un centro de investigaciones (ÂżQuiĂ©n le pone el cascabel al gato?)
Esperanza de vida ajustada por cardiopatĂa isquĂ©mica Ischemic heart disease adjusted life expectancy
La cardiopatĂa isquĂ©mica es una de las enfermedades crĂłnicas no transmisibles de mayor impacto por su morbilidad y mortalidad. En Cuba, con respecto a la morbilidad, este impacto no se ha cuantificado en un Ășnico Ăndice que tenga en cuenta la severidad de esta enfermedad. La esperanza de vida ajustada por discapacidad (EVAD) es un indicador relativamente reciente que permite cuantificar el efecto de la morbilidad por cualquier enfermedad, particularmente la cardiopatĂa isquĂ©mica, sobre la esperanza de vida. En este trabajo se aplica la EVAD para el caso especĂfico de la cardiopatĂa isquĂ©mica, en los años 1990, 1995 y 2000, lo que facilita el estudio comparativo del impacto de la morbilidad por esta enfermedad entre hombres y mujeres y a lo largo del perĂodo abarcado por estos 3 años. Se observa que el efecto negativo de la morbilidad por cardiopatĂa isquĂ©mica sobre la esperanza de vida aumenta de manera importante a lo largo del perĂodo estudiado; la morbilidad tiene un impacto ligeramente mayor en las mujeres que en los hombres en los 3 años analizados. La carga de la morbilidad por cardiopatĂa isquĂ©mica tiende a aumentar con la edad en cada uno de los 3 años que se estudian.Ischemic heart disease, is one of the noncommunicable chronic diseases of highest impact due to its morbidity and mortality. In Cuba, as regards mortality, this impact has not been quantified by a unique index that takes into account the severity of the disease. The disability adjusted life expectancy (DALE) is a relatively recent indicator that allows to quantify the effect of morbidity from any disease, mainly ischemic heart disease, on life expectancy. In this paper, DALE is specifically applied to ischemic heart disease in 1990, 1995 and 2000, which makes easy the comparative study of the impact of morbidity from this disease between males and females and along these 3 years. It is observed that the negative effect of morbidity from ischemic heart disease on life expectancy increases in a significant way in the studied period, and that morbidity has a slightly greater impact on females. The burden of morbidity from ischemic heart disease tends to rise with age in each of the analyzed years
Evolution of disease mortality burden in Cuba: 1990-2005
The objective of this study was to estimate the evolution of the burden of disease in Cuba for 20 major causes at five year intervals from 1990 to 2005, in terms of mortality and years of life lost due to premature death (YLL), using national mortality registries. Six summary measures were computed for each of the 20 major causes of death which characterized the evolution of the disease burden over the period studied. The 20 causes were then grouped according to their behaviour in these summary measures; hierarchical cluster analysis was used to support this grouping process. We compute YLL results with and without age-weighting and time discounting (3%). The 20 major causes were grouped into 12 subgroups, each with a particular pattern. The burden of disease in Cuba during the period 1990-2005 has a peculiar pattern that does not reproduce the one characteristic of other low- and middle-income countries. The approach used in this study supports a better description of mortality and YLL trends for major causes, for identifying possible explanations, and for supporting public health policy making. It seems convenient to reproduce this analysis using shorter time intervals, e.g. annually